Comparing GLP-1 and Dual Agonists for Superior Weight Loss Outcomes

The global prevalence of obesity continues to rise, posing significant health challenges and increasing the risk of numerous comorbidities like type 2 diabetes and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as highly effective pharmacological interventions for weight management. However, with the introduction of newer dual agonists (targeting both GLP-1 and GIP receptors), clinicians and patients lack a comprehensive, head-to-head comparison of their relative efficacy and safety profiles. This study addresses the crucial knowledge gap regarding which specific GLP-1 receptor or dual agonist offers the most significant and sustained weight loss benefits.

The network meta-analysis revealed significant differences in mean percentage body weight reduction among the various agents. Tirzepatide (a GLP-1/GIP dual agonist) consistently demonstrated superior efficacy. Tirzepatide achieved the highest mean percentage body weight reduction of -18.5% (95% CI: -20.1% to -16.9%) from baseline, significantly outperforming all other comparators (p<0.001). Specifically, tirzepatide showed a 3.2% greater weight loss compared to semaglutide (2.4 mg weekly) (p=0.003), which itself resulted in a mean reduction of -15.3% (95% CI: -16.7% to -13.9%). Liraglutide (3.0 mg daily) yielded a mean weight loss of -7.8% (95% CI: -8.9% to -6.7%), while dulaglutide (1.5 mg weekly) showed a -5.1% reduction (95% CI: -6.2% to -4.0%). All active treatments were significantly more effective than placebo, which typically showed a -2.5% (95% CI: -3.0% to -2.0%) weight change.